| Autor: |
J., Holfeld |
| Předmět: |
|
| Zdroj: |
Cardiology Research Review; 2024, Issue 114, p5-5, 1/4p |
| Abstrakt: |
The CAST-HF trial investigated the efficacy of cardiac shockwave therapy as a novel treatment option in patients with chronic ischaemic heart failure. Sixty-three patients with left ventricular ejection fraction (LVEF) =40% who were due to undergo surgical revascularisation were randomised to direct cardiac shockwave therapy or sham treatment in addition to CABG. The primary efficacy end-point was the improvement in LVEF from baseline at 1 year. The shockwave therapy group had greater improvement in LVEF at 1 year than the sham-treated group (+11.3% vs +6.3%; p=0.0146), and a greater improvement in 6-min walking distance (+127.5m vs +43.6m; p=0.028). No device-related adverse or serious adverse events were observed. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
